Evidence map›Paper›PMID 38735973›Full record

ArticleBMC cancer2024

High expression of SRSF1 facilitates osteosarcoma progression and unveils its potential mechanisms.

Shuqi Li, Xinyi Huang, Shuang Zheng, Wenhui Zhang, Fang Liu, Qinghua Cao

Abstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. YB1 and its role in osteosarcoma: a review.Frontiers in oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuqi LiDepartment of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Xinyi HuangDepartment of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Shuang ZhengDepartment of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Wenhui ZhangDepartment of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Fang LiuState Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Department of Liver Tumor Center, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. liufang7250@163.com.
Qinghua CaoDepartment of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China. caoqhua@mail.sysu.edu.cn.

Funding

National Natural Science Foundation of China Grant Nos. 81972516Natural Science Foundation of Guangdong Province Grant No. 2021A1515012448President Foundation of Nanfang Hospital, Southern Medical University Grant No. 2018B012
6 · The paper itself

Abstract

backgroundSRSF1, a member of Serine/Arginine-Rich Splicing Factors (SRSFs), has been observed to significantly influence cancer progression. However, the precise role of SRSF1 in osteosarcoma (OS) remains unclear. This study aims to investigate the functions of SRSF1 and its underlying mechanism in OS.

methodsSRSF1 expression level in OS was evaluated on the TCGA dataset, TAGET-OS database. qRT-PCR and Western blotting were employed to assess SRSF1 expression in human OS cell lines as well as the interfered ectopic expression states. The effect of SRSF1 on cell migration, invasion, proliferation, and apoptosis of OS cells were measured by transwell assay and flow cytometry. RNA sequence and bioinformatic analyses were conducted to elucidate the targeted genes, relevant biological pathways, and alternative splicing (AS) events regulated by SRSF1.

resultsSRSF1 expression was consistently upregulated in both OS samples and OS cell lines. Diminishing SRSF1 resulted in reduced proliferation, migration, and invasion and increased apoptosis in OS cells while overexpressing SRSF1 led to enhanced growth, migration, invasion, and decreased apoptosis. Mechanistically, Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and Gene Set Enrichment Analysis (GSEA) revealed that the biological functions of SRSF1 were closely associated with the dysregulation of the protein targeting processes, location of the cytosolic ribosome, extracellular matrix (ECM), and proteinaceous extracellular matrix, along with the PI3K-AKT pathway, Wnt pathway, and HIPPO pathway. Transcriptome analysis identified AS events modulated by SRSF1, especially (Skipped Exon) SE events and (Mutually exclusive Exons) MXE events, revealing potential roles of targeted molecules in mRNA surveillance, RNA degradation, and RNA transport during OS development. qRT-PCR confirmed that SRSF1 knockdown resulted in the occurrence of alternative splicing of SRRM2, DMKN, and SCAT1 in OS.

conclusionsOur results highlight the oncogenic role of high SRSF1 expression in promoting OS progression, and further explore the potential mechanisms of action. The significant involvement of SRSF1 in OS development suggests its potential utility as a therapeutic target in OS.

Indexed as

ApoptosisBone NeoplasmsCell ProliferationGene Expression Regulation, NeoplasticOsteosarcomaSerine-Arginine Splicing FactorsAlternative SplicingCell Line, TumorCell MovementDisease ProgressionHumansUp-RegulationSerine-Arginine Splicing FactorsSRSF1 protein, humanAlternative splicingOsteosarcomaRNA-sequenceSRSF1Tumor progression

Identifiers

PMID38735973
PMCPMC11088775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.